Search - tctmd.com

Displaying 141 - 160 of 275

Sort: Relevancy | Date

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

FDA Approves Two Generic Versions of Apixaban

December 23, 2019

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

News Conference News AHA 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

November 17, 2019

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

News Daily News

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Yael L. Maxwell

September 20, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

News Daily News

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Marcus A. Banks

July 12, 2019

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

June 26, 2019

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

News Daily News

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Michael O'Riordan

May 08, 2019

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

News Daily News

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Michael O'Riordan

May 06, 2019

Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD

News Daily News

Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD

February 15, 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

News Conference News ISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

News Daily News

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Michael O'Riordan

February 08, 2019

Intensive BP Lowering May Have Cognitive Benefits: SPRINT MIND

News Daily News

Intensive BP Lowering May Have Cognitive Benefits: SPRINT MIND

February 04, 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

TCTMD’s Top 10 Most Popular Stories for January 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

January 31, 2019

Top Stories in Cardiology: January 2019

Podcast Heart Sounds

Top Stories in Cardiology: January 2019

January 30, 2019

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

News Daily News

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Michael O'Riordan

January 29, 2019

Aspirin as Primary Prevention Curbs CV Events but Ups Major Bleeding, Too: Meta-analysis

News Daily News

Aspirin as Primary Prevention Curbs CV Events but Ups Major Bleeding, Too: Meta-analysis

January 24, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.